# Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

> **NCT01002274** · PHASE3 · COMPLETED · sponsor: **Health Ever Bio-Tech Co., Ltd.** · enrollment: 180 (actual)

## Conditions studied

- Lower Urinary Tract Symptoms
- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** MCS-2

## Key facts

- **NCT ID:** NCT01002274
- **Lead sponsor:** Health Ever Bio-Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2016-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01002274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01002274, "Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01002274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*